EUVIMEDEUVIMED entdecken
Crossref

Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study

Mingming Deng, Ziwen Zheng, Run Tong, Ke Huang, Ting Yang, Gang Hou

Respiration · 2025

DOI: 10.1159/000549779 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Respiration, 2025. Verfasst von Mingming Deng und 5 weiteren Autor:innen. Beteiligte Einrichtung: National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respir…. Hauptthemen laut MEDLINE: Pulmonary Emphysema, Pneumonectomy, Prostheses and Implants. Die Arbeit nennt 16 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Available endobronchial valves (EBVs) for lung volume reduction in severe emphysema are limited in variety and predominantly feature complex metal-silicone designs (e.g., Zephyr®). This study aimed to introduce a novel, all-silicone endobronchial valve (ESV) designed to simplify manufacturing and potentially improve biocompatibility.

Methods

A preclinical study implanted ESVs or Zephyr® EBVs (1:1) into unilateral caudal lobes of 8 pigs, assessed using computed tomography, bronchoscopy, and necropsy over 6 weeks. A first-in-human (FIH) trial enrolled 3 severe emphysema patients (male, aged 48–72 years, collateral ventilation-negative). ESVs were placed using a bronchoscope under general anaesthesia. Outcomes included procedural success, safety, target lobar volume reduction, lung function, quality of life, and exercise capacity at baseline and 3 and 6 months.

Results

Preclinically, all valves (12 ESV, 12 Zephyr®) were successfully implanted and removed. Complete target lobe atelectasis occurred by 6 weeks in all animals, without major adverse events; localised granulation was observed. In the FIH trial, all ESVs were successfully deployed (procedure time: 5–20 min). Target lobar volume reductions occurred at 6 months in 2 of 3 cases (Case 1: 1.5 L, Case 2: 0.4 L). Emphysema volume decreased at 3 and 6 months. Lung function, quality of life, and exercise capacity showed trends toward improvement. One patient experienced an acute exacerbation of chronic obstructive pulmonary disease; no pneumothorax, pneumonia, or haemoptysis occurred.

Conclusion

Overall, ESV was shown to have an initial feasibility for endobronchial lung volume reduction in humans. Further studies are needed to evaluate the sustained effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Pulmonary EmphysemaPneumonectomyProstheses and ImplantsAnimalsHumansMaleMiddle AgedBronchoscopyAgedSwineSiliconesProsthesis DesignTomography, X-Ray ComputedQuality of Life

Stichwörter der Autor:innen

Chronic obstructive pulmonary diseaseEmphysemaEndobronchial lung volume reductionEndobronchial valve

Substanzen

Silicones

Autor:innen und Institutionen

  • National Center for Respiratory Medicine, State Key Laboratory of Respiratory Health and Multimorbidity, National Clinical Research Center for Respiratory Diseases, Institute of Respiratory Medicine, Chinese Academy of…
  • China-Japan Friendship Hospital (Institute of Clinical Medical Sciences), Chinese Academy of Medical Science and Peking Union Medical College, Beijing, China.

Zitieren

APA

Deng, M., Zheng, Z., Tong, R., Huang, K., Yang, T., & Hou, G. (2025). Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study. Respiration. https://doi.org/10.1159/000549779

Vancouver

Deng M, Zheng Z, Tong R, Huang K, Yang T, Hou G. Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study. Respiration. 2025. doi:10.1159/000549779

BibTeX
@article{Deng2025,
  author = {Deng, Mingming and Zheng, Ziwen and Tong, Run and Huang, Ke and Yang, Ting and Hou, Gang},
  title = {Novel Endobronchial Silicone Valve for Treating Lung Emphysema: A Preclinical Trial and First-In-Human Study},
  journal = {Respiration},
  year = {2025},
  doi = {10.1159/000549779}
}
Kostenlos starten →